Antimicrobial peptides: a promising strategy for lung cancer drug discovery?

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan 01;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• de Groot PM, Wu CC, Carter BW, et al. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018;7(3):220–233.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 01;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Lum C, Technological AM. Therapeutic advances in advanced small cell lung cancer. Cancers (Basel). 2019 Oct 15;11(10). DOI:10.3390/cancers11101570.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019 Sep;19(9):495–509.
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May 01;83(5):584–594.
   PubMed Web of Science ®Google Scholar
• Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Canc Netw. 2013 Jan 1;11(1):78–98.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017 Jan 21;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Suda K, Wiens J, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 03;388(10048):1012–1024.
   PubMed Web of Science ®Google Scholar
• Aghapour M, Raee P, Moghaddam SJ, et al. Airway epithelial barrier dysfunction in chronic obstructive pulmonary disease: role of cigarette smoke exposure. Am J Respir Cell Mol Biol. 2018 Feb 01;58(2):157–169.
   PubMed Web of Science ®Google Scholar
• Zugazagoitia J, Guedes C, Ponce S, et al. Current challenges in cancer treatment. Clin Ther. 2016 Jul 01;38(7):1551–1566.
   PubMed Web of Science ®Google Scholar
• Tartarone A, Giordano P, Lerose R, et al. Progress and challenges in the treatment of small cell lung cancer. Med Oncol. 2017 Apr 29;34(6):110.
   PubMed Web of Science ®Google Scholar
• Yu G, Baeder DY, Regoes RR, et al. Combination effects of antimicrobial peptides. Antimicrob Agents Chemother. 2016;60(3):1717. .
   PubMed Web of Science ®Google Scholar
• Hancock REW, Haney EF, Gill EE. The immunology of host defence peptides: beyond antimicrobial activity. Nat Rev Immunol. 2016 May 01;16(5):321–334.
   PubMed Web of Science ®Google Scholar
• He X, Yang S, Wei L, et al. Antimicrobial peptide diversity in the skin of the torrent frog, Amolops jingdongensis. Amino Acids. 2013 Feb 01;44(2):481–487.
   PubMed Web of Science ®Google Scholar
• Schmitt P, Rosa RD, Destoumieux-Garzón D. An intimate link between antimicrobial peptide sequence diversity and binding to essential components of bacterial membranes. Biochim Biophys Acta - Biomembr. 2016 May 01;1858(5):958–970.
   Web of Science ®Google Scholar
• Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence. 2010 Sep 01;1(5):440–464.
   PubMed Web of Science ®Google Scholar
• Dennison SR, Harris F, Bhatt T, et al. A theoretical analysis of secondary structural characteristics of anticancer peptides. Mol Cell Biochem. 2009 Jul 21;333(1):129.
   PubMed Web of Science ®Google Scholar
• Migoń D, Neubauer D, Kamysz W. Hydrocarbon stapled antimicrobial peptides. Protein J. 2018 Feb 01;37(1):2–12.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Silverberg JI. New therapies for atopic dermatitis: additional treatment classes. J Am Acad Dermatol. 2018 Mar 01;78(3, Supplement 1):S76–S83.
   PubMed Web of Science ®Google Scholar
• Trivedi MK, Bosanac SS, Sivamani RK, et al. Emerging therapies for acne vulgaris. Am J Clin Dermatol. 2018 Aug 01;19(4):505–516.
   PubMed Web of Science ®Google Scholar
• Madden GR, Sifri CD. Antimicrobial resistance to agents used for staphylococcus aureus decolonization: is there a reason for concern? Curr Infect Dis Rep. 2018 Jun 07;20(8):26.
   PubMed Web of Science ®Google Scholar
• Dolkar T, Trinidad CM, Nelson KC, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018 jul 01;45(7):539–544.
   PubMed Web of Science ®Google Scholar
• Gronberg A, Mahlapuu M, Stahle M, et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. 2014 Sep-Oct;22(5):613–621.
   PubMed Web of Science ®Google Scholar
• Sierra JM, Fusté E, Rabanal F, et al. An overview of antimicrobial peptides and the latest advances in their development. Expert Opin Biol Ther. 2017 Jun 03;17(6):663–676.
   PubMed Web of Science ®Google Scholar
• Sztukowska MN, Roky M, Demuth DR. Peptide and non-peptide mimetics as potential therapeutics targeting oral bacteria and oral biofilms. Mol Oral Microbiol. 2019 Oct 01;34(5):169–182.
   PubMed Web of Science ®Google Scholar
• Baker JL, He X, Shi W. Precision reengineering of the oral microbiome for caries management. Adv Dent Res. 2019 Nov 01;30(2):34–39.
   PubMedGoogle Scholar
• Milgrom PM, Horst JA. The effect of new oral care technologies on the need for dentists in 2040. J Dent Educ. 2017;81(8):eS126.
   PubMedGoogle Scholar
• Silva JP, Appelberg R, Gama FM. Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv. 2016 Sep 01;34(5):924–940.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Dale GE, Torres A. Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther. 2018 Apr 03;16(4):259–268.
   PubMed Web of Science ®Google Scholar
• Bader JC, Lakota EA, Dale GE, et al. Pharmacokinetic-pharmacodynamic evaluation of ertapenem for patients with hospital-acquired or ventilator-associated bacterial pneumonia. Antimicrob Agents Chemother. 2019;63(6):e00318–19.
   PubMed Web of Science ®Google Scholar
• Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnol Reports. 2017 Sep 01;15:24–26. .
   Google Scholar
• Sun E, Belanger CR, Haney EF, et al. 10 - Host defense (antimicrobial) peptides. In: Koutsopoulos S, editor. Peptide applications in biomedicine, biotechnology and bioengineering. Cambridge (UK): Woodhead Publishing; 2018. p. 253–285.
   Google Scholar
• Molchanova N, Hansen RP, Franzyk H. Advances in development of antimicrobial peptidomimetics as potential drugs. Molecules. 2017;22:9.
   Web of Science ®Google Scholar
• Easton DM, Nijnik A, Mayer ML, et al. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 2009 Oct 01;27(10):582–590.
   PubMed Web of Science ®Google Scholar
• Yeung ATY, Gellatly SL, Hancock REW. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci. 2011 May 15;68(13):2161.
   PubMed Web of Science ®Google Scholar
• Sortino O, Hullsiek KH, Richards E, et al. The effects of recombinant human lactoferrin on immune activation and the intestinal microbiome among persons living with human immunodeficiency virus and receiving antiretroviral therapy. J Infect Dis. 2019;219(12):1963–1968.
   PubMed Web of Science ®Google Scholar
• Butler MS, Blaskovich MAT, Cooper MA. Antibiotics in the clinical pipeline at the end of 2015. J Antibiot (Tokyo). 2017 Jan 01;70(1):3–24.
   PubMed Web of Science ®Google Scholar
• Nilsson AC, Janson H, Wold H, et al. LTX-109 is a novel agent for nasal decolonization of methicillin-resistant and -sensitive staphylococcus aureus. Antimicrob Agents Chemother. 2015;59(1):145–151. .
   PubMed Web of Science ®Google Scholar
• Wang J, Dou X, Song J, et al. Antimicrobial peptides: promising alternatives in the post feeding antibiotic era. Med Res Rev. 2019 May 01;39(3):831–859.
   PubMed Web of Science ®Google Scholar
• Battersby AJ, Khara J, Wright VJ, et al. Antimicrobial proteins and peptides in early life: ontogeny and translational opportunities [10.3389/fimmu.2016.00309]. Front Immunol. 2016;7:309.
   PubMed Web of Science ®Google Scholar
• Brouwer CPJM, Rahman M, Welling MM. Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides. 2011 Sep 01;32(9):1953–1963.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E. Development of novel antibacterial drugs to combat multiple resistant organisms. Langenbecks Arch Surg. 2015 Feb 01;400(2):153–165.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Rhomberg PR, Farrell DJ, et al. In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. Diagn Microbiol Infect Dis. 2016 Sep 01;86(1):66–69.
   PubMed Web of Science ®Google Scholar
• Javia A, Amrutiya J, Lalani R, et al. Antimicrobial peptide delivery: an emerging therapeutic for the treatment of burn and wounds. Ther Deliv. 2018 May 01;9(5):375–386.
   PubMed Web of Science ®Google Scholar
• van Groenendael R, Beunders R, Kox M, et al. The human chorionic gonadotropin derivate EA-230 modulates the immune response and exerts renal protective properties: therapeutic potential in humans. Semin Nephrol. 2019 Sep;39(5):496–504. .
   PubMed Web of Science ®Google Scholar
• van Groenendael R, Aarnoutse R, Kox M, et al. Pharmacokinetics, safety and tolerability of the novel beta-hCG derived immunomodulatory compound, EA-230. Br J Clin Pharmacol. 2019 Jul;85(7):1572–1584. .
   PubMed Web of Science ®Google Scholar
• Domingues MM, Santos NC, Castanho MA. Antimicrobial peptide rBPI21: a translational overview from bench to clinical studies. Curr Protein Pept Sci. 2012 Nov;13(7):611–619.
   PubMed Web of Science ®Google Scholar
• Raghay K, Akki R, Bensaid D, et al. Ghrelin as an anti-inflammatory and protective agent in ischemia/reperfusion injury. Peptides. 2020 Feb;124:170226.
   PubMed Web of Science ®Google Scholar
• Schalla MA, Stengel A. LEAP2: A novel regulator of food intake and body weight? Nat Clin Pract Gastroenterol Hepatol. 2019 Dec 01;16(12):711–712.
   Google Scholar
• Kudrimoti M, Curtis A, Azawi S, et al. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115–125.
   PubMed Web of Science ®Google Scholar
• Blakaj A, Bonomi M, Gamez ME, et al. Oral mucositis in head and neck cancer: evidence-based management and review of clinical trial data. Oral Oncol. 2019 Aug;95:29–34.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Girard L, Lockwood WW, et al. Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst. 2010 Sep 8;102(17):1310–1321.
   PubMedGoogle Scholar
• Du A, Jiang Y, Fan C. NDRG1 downregulates ATF3 and inhibits cisplatin-induced cytotoxicity in lung cancer A549 cells. Int J Med Sci. 2018;15(13):1502–1507.
   PubMed Web of Science ®Google Scholar
• Camerlingo R, Miceli R, Marra L, et al. Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation. PLoS One. 2019;14(7):e0219597.
   PubMed Web of Science ®Google Scholar
• Zhang H, Feng QQ, Gong JH, et al. Anticancer effects of isofraxidin against A549 human lung cancer cells via the EGFR signaling pathway. Mol Med Rep. 2018 Jul;18(1):407–414. .
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang M, Du C, et al. Utilization of lung cancer cell lines for the study of lung cancer stem cells. Oncol Lett. 2018 May;15(5):6791–6798. .
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Sun JM, Lee SH, et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf. 2017 Apr;16(4):465–469. .
   PubMed Web of Science ®Google Scholar
• Yang F, Li Y, Liu B, et al. Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models. Exp Cell Res. 2018 Jan 1;362(1):195–202.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer. 2010 Jun;68(3):309–318.
   PubMed Web of Science ®Google Scholar
• Roed H, Vindeløv LL. Can human small-cell lung cancer cell lines be applied for optimizing chemotherapy? Cancer Treat Res. 1989;45:151–172.
   PubMedGoogle Scholar
• Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014 May 1;74(9):2377–2384.
   PubMed Web of Science ®Google Scholar
• Melo MN, Ferre R, Feliu L, et al. Prediction of antibacterial activity from physicochemical properties of antimicrobial peptides. Plos One. 2011;6(12):e28549. .
   PubMed Web of Science ®Google Scholar
• Yavari B, Mahjub R, Saidijam M, et al. The potential use of peptides in cancer treatment. Current Protein Pept Sci. 2018;19(8):759–770. .
   PubMed Web of Science ®Google Scholar
• Utsugi T, Schroit AJ, Connor J, et al. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991;51(11):3062.
   PubMed Web of Science ®Google Scholar
• Kim IW, Lee JH, Kwon YN, et al. Anticancer activity of a synthetic peptide derived from harmoniasin, an antibacterial peptide from the ladybug Harmonia axyridis. Int J Oncol. 2013 Aug;43(2):622–628.
   PubMed Web of Science ®Google Scholar
• Berger M, Motta C, Boiret N, et al. Membrane fluidity and adherence to extracellular matrix components are related to blast cell count in acute myeloid leukemia. Leuk Lymphoma. 1994 Oct;15(3–4):297–302. .
   PubMed Web of Science ®Google Scholar
• Sok M, Šentjurc M, Schara M, et al. Cell membrane fluidity and prognosis of lung cancer. Ann Thorac Surg. 2002 May 01;73(5):1567–1571.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lin J, Lu ML, et al. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 2002;62(8):2227.
   PubMed Web of Science ®Google Scholar
• Papaccio F, Paino F, Regad T, et al. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med. 2017 Dec 01;6(12):2115–2125.
   PubMed Web of Science ®Google Scholar
• Felicio MR, Silva ON, Goncalves S, et al. Peptides with dual antimicrobial and anticancer activities. Front Chem. 2017;5:5.
   PubMed Web of Science ®Google Scholar
• Peng KC, Lee SH, Hour AL, et al. Five different piscidins from Nile tilapia, Oreochromis niloticus: analysis of their expressions and biological functions. PLoS One. 2012;7(11):e50263.
   PubMed Web of Science ®Google Scholar
• Ting C-H, Chen J-Y. Nile tilapia derived TP4 shows broad cytotoxicity toward to non-small-cell lung cancer cells. Mar Drugs. 2018;16(12):506.
   Web of Science ®Google Scholar
• Ting C-H, Liu Y-C, Lyu P-C, et al. Nile tilapia derived antimicrobial peptide TP4 exerts antineoplastic activity through microtubule disruption. Mar Drugs. 2018;16(12):462.
   Web of Science ®Google Scholar
• Jiang S, Jia Y, Tang Y, et al. Anti-proliferation activity of a decapeptide from perinereies aibuhitensis toward human lung cancer H1299 cells. Mar Drugs. 2019;17(2):122. .
   Web of Science ®Google Scholar
• Yu HY, Huang KC, Yip BS, et al. Rational design of tryptophan-rich antimicrobial peptides with enhanced antimicrobial activities and specificities. Chembiochem. 2010 Nov 2;11(16):2273–2282.
   PubMed Web of Science ®Google Scholar
• Chu HL, Yip BS, Chen KH, et al. Novel antimicrobial peptides with high anticancer activity and selectivity. PLoS One. 2015;10(5):e0126390. .
   PubMed Web of Science ®Google Scholar
• Lei J, Sun L, Huang S, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019;11(7):3919–3931.
   PubMed Web of Science ®Google Scholar
• Ciumac D, Gong H, Hu X, et al. Membrane targeting cationic antimicrobial peptides. J Colloid Interface Sci. 2019 Mar 01;537:163–185. .
   PubMed Web of Science ®Google Scholar
• Mookherjee N, Anderson MA, Haagsman HP, et al. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020 May 01;19(5):311–332.
   PubMed Web of Science ®Google Scholar
• Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002 Jan 01;415(6870):389–395.
   PubMed Web of Science ®Google Scholar
• Divyashree M, Mani MK, Reddy D, et al. Clinical applications of antimicrobial peptides (AMPs): where do we stand now? Protein Pept Lett. 2020;27(2):120–134.
   PubMed Web of Science ®Google Scholar
• Aaghaz S, Gohel V, Kamal A. Peptides as potential anticancer agents. Curr Top Med Chem. 2019;19(17):1491–1511. .
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Ishibashi J, Tanaka H, et al. Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides. 2009 Apr 01;30(4):660–668.
   PubMed Web of Science ®Google Scholar
• Boohaker J, R W, Lee M, et al. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012;19(22):3794–3804. .
   PubMed Web of Science ®Google Scholar
• Deslouches B, Di YP. Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget. 2017;8(28):46635–46651.
   PubMedGoogle Scholar
• Tarp MA, Clausen H. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta Gen Subj. 2008 Mar 01;1780(3):546–563.
   PubMed Web of Science ®Google Scholar
• Wu X, Pan J, Wu Y, et al. PSN-PC: a novel antimicrobial and anti-biofilm peptide from the skin secretion of phyllomedusa-camba with cytotoxicity on human lung cancer cell. Molecules. 2017;22(11):1896. .
   PubMed Web of Science ®Google Scholar
• Liu J, Wu Q, Li L, et al. Discovery of phylloseptins that defense against gram-positive bacteria and inhibit the proliferation of the non-small cell lung cancer cell line, from the skin secretions of phyllomedusa frogs. Molecules. 2017;22:9.
   Web of Science ®Google Scholar
• Hansen T, Ausbacher D, Zachariassen ZG, et al. Anticancer activity of small amphipathic β2,2-amino acid derivatives. Eur J Med Chem. 2012 Dec 01;58:22–29. .
   PubMed Web of Science ®Google Scholar
• Guy Evans H,W, Guthrie J, Jujjavarapu M, et al. D-amino acid analogues of the antimicrobial peptide CDT exhibit anti- cancer properties in A549, a human lung adenocarcinoma cell line. Protein Pept Lett. 2017;24(7):590–598. .
   PubMed Web of Science ®Google Scholar
• Ting C-H, Lee K-Y, Wu S-M, et al. FOSB–PCDHB13 axis disrupts the microtubule network in non-small cell lung cancer. Cancers (Basel). 2019;11:1.
   Web of Science ®Google Scholar
• Ashitani J-I, Nakazato M, Mukae H, et al. Recombinant granulocyte colony-stimulating factor induces production of human neutrophil peptides in lung cancer patients with neutropenia. Regul Pept. 2000 Nov 24;95(1):87–92.
   PubMedGoogle Scholar
• Mahlapuu M, Håkansson J, Ringstad L, et al. Antimicrobial peptides: an emerging category of therapeutic agents [10.3389/fcimb.2016.00194]. Front Cell Infect Microbiol. 2016;6:194.
   PubMed Web of Science ®Google Scholar
• Varney KM, Bonvin AMJJ, Pazgier M, et al. Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II. PLoS Pathog. 2013;9(11):e1003732. .
   PubMed Web of Science ®Google Scholar
• Hanaoka Y, Yamaguchi Y, Yamamoto H, et al. In vitro and in vivo anticancer activity of human β-defensin-3 and its mouse homolog. Anticancer Res. 2016;36(11):5999–6004. .
   PubMed Web of Science ®Google Scholar
• Fabrias G, Bedia C, Casas J, et al. Ceramidases in hematological malignancies: senseless or neglected target? Anti-Cancer Agents Med Chem. 2011;11(9):830–843.
   PubMed Web of Science ®Google Scholar
• Wang S, Tu J, Zhou C, et al. The effect of Lfcin-B on non-small cell lung cancer H460 cells is mediated by inhibiting VEGF expression and inducing apoptosis. Arch Pharm Res. 2015 Feb 01;38(2):261–271.
   PubMed Web of Science ®Google Scholar
• Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med. 2002 May 01;13(3):229–237.
   PubMedGoogle Scholar
• Danaher RJ, Savells-Arb AD, Black SA, et al. Herpesvirus quiescence in neuronal cells IV: virus activation induced by pituitary adenylate cyclase-activating polypeptide (PACAP) involves the protein kinase A pathway. J Neurovirol. 2001 Mar 01;7(2):163–168.
   PubMed Web of Science ®Google Scholar
• Elefsiniotis IS, Ketikoglou I, Kafiri G, et al. Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment. Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1209–1216. .
   PubMed Web of Science ®Google Scholar
• Lugo JM, Tafalla C, Oliva A, et al. Evidence for antimicrobial and anticancer activity of pituitary adenylate cyclase-activating polypeptide (PACAP) from North African catfish (Clarias gariepinus): its potential use as novel therapeutic agent in fish and humans. Fish Shellfish Immunol. 2019 Mar 01;86:559–570.
   PubMed Web of Science ®Google Scholar
• Koehbach J, Craik DJ. The vast structural diversity of antimicrobial peptides. Trends Pharmacol Sci. 2019 Jul 01;40(7):517–528.
   PubMed Web of Science ®Google Scholar
• Lee T-H N, Hall K, Aguilar M-I. Antimicrobial peptide structure and mechanism of action: a focus on the role of membrane structure. Curr Top Med Chem. 2016;16(1):25–39.
   PubMed Web of Science ®Google Scholar
• Tian Y, Wang H, Li B, et al. The cathelicidin-BF Lys16 mutant Cbf-K16 selectively inhibits non-small cell lung cancer proliferation in vitro. Oncol Rep. 2013 Nov;30(5):2502–2510.
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Huang H-Y, Forrest MD, et al. inhibition effect of a custom peptide on lung tumors. Plos One. 2014;9(10):e109174.
   PubMed Web of Science ®Google Scholar
• Koszałka P, Kamysz E, Wejda M, et al. Antitumor activity of antimicrobial peptides against U937 histiocytic cell line. Acta Biochim Pol. 2011;58(1):111–117.
   PubMed Web of Science ®Google Scholar
• Vragniau C, J-M H, Beidler P, et al. Studies on the interaction of tumor-derived HD5 alpha defensins with adenoviruses and implications for oncolytic adenovirus therapy. J Virol. 2017;91(6):e02030–16.
   PubMed Web of Science ®Google Scholar
• Ji P, Zhou Y, Yang Y, et al. Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling. Theranostics. 2019;9(8):2209–2223.
   PubMed Web of Science ®Google Scholar
• Hao X, Yan Q, Zhao J, et al. TAT modification of alpha-helical anticancer peptides to improve specificity and efficacy. Plos One. 2015;10(9):e0138911.
   PubMed Web of Science ®Google Scholar
• Aghamiri S, Jafarpour A, Malekshahi ZV, et al. Targeting siRNA in colorectal cancer therapy: nanotechnology comes into view. J Cell Physiol. 2019 Sep 01;234(9):14818–14827.
   Web of Science ®Google Scholar
• Aghamiri S, Mehrjardi KF, Shabani S, et al. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy? Nanomedicine. 2019 Aug 01;14(15):2083–2100.
   PubMed Web of Science ®Google Scholar
• Aghamiri S, Jafarpour A, Gomari MM, et al. siRNA nanotherapeutics: a promising strategy for anti-HBV therapy. IET Nanobiotechnol. 2019;13(5):457–463.
   Web of Science ®Google Scholar
• Aghamiri S, Talaei S, Roshanzamiri S, et al. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy. Expert Opin Drug Deliv. 2020;;17(6):753–766.
   PubMed Web of Science ®Google Scholar
• Zandsalimi F, Aghamiri S, Roshanzamiri S, et al. The emerging role of cold atmospheric plasma in glioblastoma therapy. Plasma Process Polym. 2020 Apr 28;n/a(n/a):e1900189.
   Google Scholar
• Kelly GJ, Kia -AF-A, Hassan F, et al. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells [10.1039/C6OB01815G]. Org Biomol Chem. 2016;14(39):9278–9286.
   PubMed Web of Science ®Google Scholar
• Aoki W, Kuroda K, Ueda M. Next generation of antimicrobial peptides as molecular targeted medicines. J Biosci Bioeng. 2012 Oct 01;114(4):365–370.
   PubMed Web of Science ®Google Scholar
• Tong CWS, Wu WKK, Loong HHF, et al. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Lett. 2017 Oct 01;405:100–110. .
   PubMed Web of Science ®Google Scholar
• Wang K-R, Yan J-X, Zhang B-Z, et al. Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells. Cancer Lett. 2009 Jun 08;278(1):65–72.
   PubMed Web of Science ®Google Scholar
• Ghorbani J, Rahban D, Aghamiri S, et al. Photosensitizers in antibacterial photodynamic therapy: an overview. Laser Ther. 2018 Dec 31;27(4):293–302.
   PubMedGoogle Scholar
• Aghamiri S, Jafarpour A, Zandsalimi F, et al. Effect of resveratrol on the radiosensitivity of 5-FU in human breast cancer MCF-7 cells. J Cell Biochem. 2019 Sep 01;120(9):15671–15677.
   PubMed Web of Science ®Google Scholar
• Aghamiri S, Talaei S, Ghavidel AA, et al. Nanoparticles-mediated CRISPR/Cas9 delivery: recent advances in cancer treatment. J Drug Delivery Sci Technol. 2020 Apr 01;56:101533. .
   Web of Science ®Google Scholar
• Jaber G, Dariush R, Shahin A, et al. Photosensitizers in antibacterial photodynamic therapy: an overview. Laser Ther. 2018;27(4):293–302.
   PubMedGoogle Scholar
• Moret F, Gobbo M, Reddi E. Conjugation of photosensitisers to antimicrobial peptides increases the efficiency of photodynamic therapy in cancer cells [10.1039/C5PP00038F]. Photochem Photobiol Sci. 2015;14(7):1238–1250.
   PubMed Web of Science ®Google Scholar